202 related articles for article (PubMed ID: 37329423)
1. Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.
Chiu CH; Lin MC; Wei YF; Chang GC; Su WC; Hsia TC; Su J; Wang AK; Jen MH; Puri T; Shih JY
Target Oncol; 2023 Jul; 18(4):505-515. PubMed ID: 37329423
[TBL] [Abstract][Full Text] [Related]
2. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M;
Cancer Treat Res Commun; 2021; 27():100378. PubMed ID: 33905962
[TBL] [Abstract][Full Text] [Related]
3. RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
Nadal E; Horinouchi H; Shih JY; Nakagawa K; Reck M; Garon EB; Wei YF; Kollmeier J; Frimodt-Moller B; Barrett E; Lipkovich O; Visseren-Grul C; Novello S
Drug Saf; 2022 Jan; 45(1):45-64. PubMed ID: 34928484
[TBL] [Abstract][Full Text] [Related]
4. Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
Nishio M; Seto T; Reck M; Garon EB; Chiu CH; Yoh K; Imamura F; Park K; Shih JY; Visseren-Grul C; Frimodt-Moller B; Zimmermann A; Homma G; Enatsu S; Nakagawa K;
Cancer Sci; 2020 Dec; 111(12):4510-4525. PubMed ID: 32954593
[TBL] [Abstract][Full Text] [Related]
5. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
Nakagawa K; Garon EB; Gao L; Callies S; Zimmermann A; Walgren R; Visseren-Grul C; Reck M
Cancer Chemother Pharmacol; 2022 Aug; 90(2):137-148. PubMed ID: 35841410
[TBL] [Abstract][Full Text] [Related]
6. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
Garon EB; Reck M; Nishio K; Heymach JV; Nishio M; Novello S; Paz-Ares L; Popat S; Aix SP; Graham H; Butts BD; Visseren-Grul C; Nakagawa K;
ESMO Open; 2023 Aug; 8(4):101580. PubMed ID: 37390764
[TBL] [Abstract][Full Text] [Related]
7. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome.
Nishio M; Paz-Ares L; Reck M; Nakagawa K; Garon EB; Popat S; Ceccarelli M; Graham HT; Visseren-Grul C; Novello S
Clin Lung Cancer; 2023 Jul; 24(5):415-428. PubMed ID: 37076395
[TBL] [Abstract][Full Text] [Related]
8. RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.
Nakagawa K; Nadal E; Garon EB; Nishio M; Seto T; Yamamoto N; Park K; Shih JY; Paz-Ares L; Frimodt-Moller B; Zimmermann AH; Wijayawardana S; Visseren-Grul C; Reck M
Clin Cancer Res; 2021 Oct; 27(19):5258-5271. PubMed ID: 34301751
[TBL] [Abstract][Full Text] [Related]
9. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
[TBL] [Abstract][Full Text] [Related]
10. Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic
Nishio K; Seto T; Nishio M; Reck M; Garon EB; Sakai K; Goto K; Kato T; Nakanishi Y; Takahashi T; Yamamoto N; Kiura K; Ohe Y; Tamura T; Visseren-Grul C; Frimodt-Moller B; Hozak RR; Wijayawardana SR; Zimmermann A; Homma G; Enatsu S; Nakagawa K
JTO Clin Res Rep; 2021 Jun; 2(6):100171. PubMed ID: 34590023
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
Reck M; Garon EB; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Kiura K; Widau RC; He S; Dalal R; Lee P; Nakagawa K
Clin Lung Cancer; 2018 May; 19(3):213-220.e4. PubMed ID: 29317191
[TBL] [Abstract][Full Text] [Related]
12. Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with
Nishio K; Sakai K; Nishio M; Seto T; Visseren-Grul C; Carlsen M; Matsui T; Enatsu S; Nakagawa K
Transl Lung Cancer Res; 2023 Aug; 12(8):1702-1716. PubMed ID: 37691865
[TBL] [Abstract][Full Text] [Related]
13. Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer.
Garon EB; Reck M; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Lee P; Dalal R; Liu J; He S; Treat J; Nakagawa K
Clin Lung Cancer; 2017 Jan; 18(1):96-99. PubMed ID: 27894601
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated
Yoh K; Atagi S; Reck M; Garon EB; Ponce Aix S; Moro-Sibilot D; Winfree KB; Frimodt-Moller B; Zimmermann A; Visseren-Grul C; Nakagawa K;
Curr Med Res Opin; 2020 Oct; 36(10):1667-1675. PubMed ID: 32780643
[TBL] [Abstract][Full Text] [Related]
15. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320).
Otani S; Sasaki J; Nakahara Y; Fukui T; Igawa S; Naoki K; Bessho A; Hosokawa S; Fukamatsu N; Nakamura Y; Kasai T; Sugiyama T; Tokito T; Seki N; Hamada A; Okamoto H; Masuda N
Invest New Drugs; 2021 Apr; 39(2):530-536. PubMed ID: 33159674
[TBL] [Abstract][Full Text] [Related]
17. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Wu YL; Lee JS; Thongprasert S; Yu CJ; Zhang L; Ladrera G; Srimuninnimit V; Sriuranpong V; Sandoval-Tan J; Zhu Y; Liao M; Zhou C; Pan H; Lee V; Chen YM; Sun Y; Margono B; Fuerte F; Chang GC; Seetalarom K; Wang J; Cheng A; Syahruddin E; Qian X; Ho J; Kurnianda J; Liu HE; Jin K; Truman M; Bara I; Mok T
Lancet Oncol; 2013 Jul; 14(8):777-86. PubMed ID: 23782814
[TBL] [Abstract][Full Text] [Related]
18. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
19. First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.
Landre T; Des Guetz G; Chouahnia K; Duchemann B; Assié JB; Chouaid C
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3333-3339. PubMed ID: 32632581
[TBL] [Abstract][Full Text] [Related]
20. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
Wu YL; Zhou C; Liam CK; Wu G; Liu X; Zhong Z; Lu S; Cheng Y; Han B; Chen L; Huang C; Qin S; Zhu Y; Pan H; Liang H; Li E; Jiang G; How SH; Fernando MCL; Zhang Y; Xia F; Zuo Y
Ann Oncol; 2015 Sep; 26(9):1883-1889. PubMed ID: 26105600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
